Coverage of Prandial Insulin Requirements: An Elusive Goal

Diabetes Technology and Therapeutics

Volumn 19, Issue 1, 2017, Pages 7-8

  Heinemann, Lutz ^a   Muchmore, Douglas ^b  

^a Science and Co   (Germany)

^b Kinexum   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; ANTIDIABETIC AGENT;

DIABETES CONTROL; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; INSULIN BLOOD LEVEL; INSULIN TREATMENT; NOTE; PRIORITY JOURNAL; TEST MEAL; BLOOD; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG MONITORING; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEAL; MULTIMODALITY CANCER THERAPY; PERSONALIZED MEDICINE; POSTPRANDIAL STATE;

COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MEALS; POSTPRANDIAL PERIOD; PRECISION MEDICINE;

EID: 85010005915     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2016.0449     Document Type: Note

References (9)

1. Heinemann L, Heise T, Wahl Ch, et al.: Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients using the rapid acting insulin analogue [Lys(B28), Pro(B29)]. Diabet Med 1996;13:625-629.
2. Heinemann L, Muchmore DB: Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol 2012;6:728-742.
3. Luijf YM, van Bon AC, Hoekstra JB, DeVries JH: Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 2010;33: 2152-2155.
4. Cobry E, McFann K, Messer L, et al.: Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther 2010;12: 173-177.
5. Heinemann L, Baughman R, Boss A, Hompesch M: Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. J Diabetes Sci Technol 2016. [Epub ahead of print]; DOI: 1932296816658055.
6. Muchmore DB: The need for faster insulin: problem solved? J Diabetes Sci Technol 2016. [Epub ahead of print]; DOI: 10.1177/193229681667757.
7. Russel-Jones DL, Bode B, De Block C, et al.: Double-blind mealtime faster-acting insulin aspart vs. isulin aspart in basal-bolus improves glycemic control in T1D: the Onset-1 trial. Can J Diabetes 2016;40 (Suppl). DOI: 10.1016/j.jcjd .2016.08.162.
8. Bode BW, Johnson JA, Hyveled L, et al.: Improved postprandial glycemic control with faster-acting insulin aspart in patients with type 1 diabetes using continuous sucutaneous insulin infusion. Diabetes Technol Ther 2017;19:25-33.
9. Andersen G, Meiffren G, Alluis B, et al.: Ultra-rapid Bio-Chaperone lispro ameliorates postprandial blood glucose control compared to insulin lispro commercial formulation in subjects with type 1 diabetes mellitus. Diabetologia 2016; 59 (Suppl):S5.